Literature

NGAL-literature

There is a considerable body of literature describing the role of NGAL. Here we provide a summary of some of the most interesting and relevant recent publications. These provide a good overview of the current state of knowledge. Additionally there are also links to relevant searches on the NCBI Pubmed site where a comprehensive list can be found.

If you would like to recommend or submit other resources and AKI or NGAL literature please contact us.

 

Key NGAL Scientific Literature

 

NGAL in Cancer and other Disease

Candido, S. et al. Roles of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Human Cancer
Chakraborty, S et al. The Multifaceted Roles of NGAL in Inflammation and Cancer.

 Search for more recent papers on NCBI (Pubmed) relating to NGAL and cancer  Search for more recent papers on NCBI (Pubmed) relating to NGAL and inflammation

 

NGAL in Drug development

Burt D et al. Application of Emerging Biomarkers of AKI in Development of Polypeptide-based Antibiotics.
Waring, W.S. & Moonie, A. Earlier Recognition of Nephrotoxicity using Novel Biomarkers of AKI

Search for more recent papers on NCBI (Pubmed) relating to NGAL in drug development

 

 

Publications using BioPorto NGAL Assays

 

Hasse-Fielitz A, Haase M, Devarajan P Cho E, Yang HN, Jo SK, Cho WY, Kim HK Di NM, Ficarella A, Ricci Z, Luciano R, Stoppa F, Picardo S, Picca S, Muraca M, Cogo P Kashani K et al. Kift RL et al.

 

General Biology of NGAL

 

NGAL in Sepsis

Huber et al. Kim et al.

Search for more recent papers on NCBI (Pubmed) relating to NGAL and sepsis

 

General NGAL Papers

 Haase et al. 2011 Med Lab News: NGAL The Diverse Biomarker Lippi et al.: NGAL Evaluation  Tiranathanagul et al.

Search for more recent papers on NCBI (Pubmed) relating to NGAL

 

 

 

 

About the NGAL Assay

Although NGAL is best known as being a biomarker of acute kidney injury (AKI), and is proving to be of great value in drug development in this context, it is now being implicated in as a key component of a number of other pathways and disease states. These include cancer, inflammation and sepsis.

Our sensitive and reliable ELISA based NGAL assays provide a reliable and sensitive means of measuring NGAL levels in both pharmaceutical and medical research settings.

Read More